Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
Enzo Life Sciences Inc. is seeking to undo a district court decision finding one of its DNA detection patents was invalid ( Enzo Life Sciences, Inc. v. Hologic, Inc. , Fed. Cir., No. 17-02355, notice of appeal filed 7/31/17 ); ( Enzo Life Sciences, Inc. v. Gen-Probe, Inc. , Fed. Cir., No. 17-02354, notice of appeal filed 7/31/17 ).
The New York-based company filed two notices of appeal with the U.S. Court of Appeals for the Federal Circuit July 31. Enzo wants the appeals court to take another look at decisions in favor of Hologic Inc. and Gen-Probe Inc. (now part of Hologic). Hologic acquired San Diego-based Gen-Probe in 2012.
Enzo and Hologic, based in Marlborough, Mass., compete in the gene testing market. Depending on how the market is defined, analysts such as Grand View Research Inc. and Mordor Intelligence estimate its global value will range from $10 billion to $25 billion by 2022, so it’s no surprise that Enzo is fighting fiercely to protect its intellectual property.
Enzo is appealing a final judgment by Judge Leonard Stark of the U.S. District Court for the District of Delaware entered July 17 finding Hologic showed Enzo’s U.S. Patent No. 6,992,180 was invalid for nonenablement. Patents can be held invalid if they don’t adequately disclose the claimed invention and enable others to practice that invention without having to engage in excessive experimentation to do so.
In 2012, Enzo sued 11 life sciences companies, including Hologic and Gen-Probe, for infringement of its patents for genetic identification and testing. Although several of those companies reached settlements with Enzo, Hologic did not.
Desmarais LLP, New York, and Farnan LLP, Wilmington, Del., represent Enzo.
To contact the reporter on this story: Dana A. Elfin in Washington at email@example.com
To contact the editor responsible for this story: Brian Broderick at firstname.lastname@example.org
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)